Chronic myeloid leukemia therapy: Focus on second-generation tyrosine kinase inhibitors

Cancer Control

Volumn 16, Issue 2, 2009, Pages 132-140

  McFarland, K Leigh ^a   Wetzstein, Gene A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALUMINUM MAGNESIUM HYDROXIDE; BOSUTINIB; BREAKPOINT CLUSTER REGION PROTEIN; DASATINIB; FAMOTIDINE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MIDAZOLAM; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; SIMVASTATIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; NAUSEA; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

EID: 65249151901     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600205     Document Type: Review

References (55)

1. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007;12(5):327-340. Epub 2007 Oct 22.
2. Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109(11):2171-2181.
3. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-172.
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-3356.
5. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
6. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1): 139-145.
7. Imatinib (Gleevec®) [Prescribing Information]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2006.
8. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
9. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355 (23):2408-2417.
10. Aoki T, Kantarjian H, O'Brien S, et al. High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML. Blood (ASH Annu Meet Abstracts). 2006;108. Abstract 2143.
11. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up on 1027 patients with late chronic-phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood (ASH Annu Meet Abstracts). 2004;104. Abstract 23.
12. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004; 18(8):1321-1331.
13. Litzow MR. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med. 2006;130(5):669-679.
14. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172-187.
15. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-880. Epub 2001 Jun 21.
16. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005;103(8):1659-1669.
17. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190-2196.
18. Dasatinib (Sprycel®) [Prescribing Information]. Princeton, New Jersey: Bristol-Myers Squibb Company; 2006.
19. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazine-l-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27)7:6658-6661.
20. Schittenhelm MM, Shiraga S, Shroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481.
21. Lee FY, Lombardo L, Camuso A, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res. 2005;46:159. Abstract 675.
22. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505.
23. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1): 286-291. Epub 2006 Jan 24.
24. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11): 5790-5797.
25. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354 (24):2531-2541.
26. Lee FY, Wen M-L, Bhide R, et al. Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML). Blood (ASH Annu Meet Abstracts). 2005;106. Abstract 1994.
27. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104(12): 3739-3745. Epub 2004 Aug 17.
28. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-1206. Epub 2008 Apr 10.
29. Stone RM, Kantarjian HM, Baccarani M, et al. Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). Blood (ASH Annu Meet Abstracts). 2007;110. Abstract 734.
30. Mauro M, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008;26(15S May 20 suppl). Abstract 7009.
31. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109 (10):4143-4150. Epub 2007 Jan 30.
32. Guilhot F, Apperley JF, Kim DW, et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood (ASH Annu Meet Abstracts). 2007;110. Abstract 470.
33. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8): 3207-3213. Epub 2006 Dec 21.
34. Gambacorti C, Cortes J, Kim DW, et al. Efficacy and safety of dasa-tinib in patients with CML in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood (ASH Annu Meet Abstracts). 2007;110. Abstract 472.
35. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results from a phase 2 study. Blood. 2007;110(7):2309-2315. Epub 2007 May 11.
36. Porkka K, Simonsson B, Dombret H, et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-0-15). Blood (ASH Annu Meet Abstracts). 2007;110. Abstract 2810.
37. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143-5150. Epub 2007 Feb 22.
38. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resis-tant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354(24):2531-2541.
39. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerabil-ity in Imatinib-resistant and-intolerant chronic phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212. Epub 2008 Jun 9.
40. Pasquini R, Ottmann OG, Goh YT, et al. Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: one-year results of CA180-035. J Clin Oncol. 2007 ASCO Annu Meet Proc(Post-Meet Ed). 2007;25(18S June 20 suppl). Abstract 7025.
41. Nilotinib (Tasigna®) [Prescribing Information]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2007.
42. Weisberg E, Manley P Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141.
43. Weisberg E, Manley PW, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765-1769. Epub 2006 May 23.
44. Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005;104(6):1230-1236.
45. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopy-rimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11(13):4941-4947.
46. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354 (24):2542-2551.
47. Kantarjian HM, Giles F, Gatterman N, et al. Nilotinib (formerly AMN107), a highly effective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-3546. Epub 2007 Aug 22.
48. Kantarjian HM, Giles FJ, Hochhaus A, et al. Nilotinib in patients with imatinib-resistant or-intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008;26(15S May 20 suppl). Abstract 7010.
49. le Coutre P, Giles FJ, Apperley J, et al. Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or-intolerance: update of a phase II study. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008;26(15 Suppl). Abstract 7050.
50. Larson R, Ottman O, Kantarjian H, et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol. 2007 ASCO Annu Meet Proc (Post-Meet Ed). 2007;25(18S June 20 suppl). Abstract 7040.
51. Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008;26(15 suppl). Abstract 7017.
52. Abruzzese E, Alimena G, le Coutre P, et al. Nilotinib in chronic mye-logenous leukemia patients who failed prior imatinib and dasatinib therapy: updated results of an open-label phase II study. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008;26(15 suppl). Abstract 7055.
53. Cortes J, Bruemmendorf T, Kantarjian H, et al. Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic mye-logenous leukemia (CML). Blood (ASH Annu Meet Abstracts). 2007;110. Abstract 733.
54. Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, et al. Bosu-tinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL. Blood (ASH Annu Meet Abstracts). 2007;110. Abstract 473.
55. Craig AR, Kantarjian HM, Cortes JE, et al. A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant to ima-tinib. J Clin Oncol. 2007 ASCO Annu Meet Proc (Post-Meet Ed). 2007;25 (18S June 20 suppl). Abstract 7046.